According to the DREAMseq phase III clinical trial, the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) (N/I), followed by the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) (D/T) if there was disease progression, led to a significant improvement in estimated 2-year overall survival from the start of treatment (72%) when compared to the opposite treatment sequence (52%).
Two studies led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center provide insight into how the immune system can successfully be activated against glioblastoma while revealing why these therapies have historically fallen short.
